In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a ...

The cash deal will add an experimental drug for moderate to severe atopic dermatitis, building up AbbVie’s core business.

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the ...

A defense system that cannot distinguish friend from stranger eventually harms the organization it is supposed to protect.

For people living with immune-mediated inflammatory diseases (IMIDs), symptoms can become part of daily life in ways that are often invisible to others. These diseases, which include conditions like ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. Read why I only rate SYRE stock a ...

AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10. 9 billion, ...

Researchers from Rosalind Franklin University's Reproductive Immunology program, which is ranked No. 1 in the world by ...

Opponents of the ballot measure criticize the potential cost of the ballot measure. Advocates say the $8.4 billion state bond ...

Johns Hopkins University has established a Planning Committee for Immunology, a first step toward creating a new interdivisional entity to advance research in the field. Immunology is a branch of ...